150 related articles for article (PubMed ID: 34796484)
1. Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis.
Yamazaki K; Suzuki S; Kawaguchi T
Br J Haematol; 2022 Mar; 196(5):1130. PubMed ID: 34796484
[No Abstract] [Full Text] [Related]
2. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
[No Abstract] [Full Text] [Related]
3. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
4. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
[No Abstract] [Full Text] [Related]
5. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
6. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
[TBL] [Abstract][Full Text] [Related]
7. [Janus kinase inhibitors as a new therapeutic principle].
Heinzl S
Med Monatsschr Pharm; 2012 Oct; 35(10):350-2. PubMed ID: 23094577
[No Abstract] [Full Text] [Related]
8. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
9. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
10. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
[No Abstract] [Full Text] [Related]
11. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
[No Abstract] [Full Text] [Related]
12. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT; Sun L; Mascarenhas J; Kiladjian JJ; Vannucchi AM; Wang J; Xia Q; Zhu E; Feller F; Rizo A; Bussolari J; Wan Y; Komrokji R
Ann Hematol; 2022 Jan; 101(1):139-146. PubMed ID: 34622316
[TBL] [Abstract][Full Text] [Related]
13. Paradigm shift: combination BET and JAK inhibition in myelofibrosis.
Mascarenhas J; Gerds A; Verstovsek S
Leukemia; 2021 Dec; 35(12):3361-3363. PubMed ID: 34480105
[No Abstract] [Full Text] [Related]
14. Title Page - Contrast-Enhanced Ultrasound of Nodular Splenic Extramedullary Hematopoiesis in a Patient with Underlying Primary Myelofibrosis.
Hajdu SD; de Leval L; Meuwly JY
Ultraschall Med; 2016 Oct; 37(5):447-450. PubMed ID: 26331329
[No Abstract] [Full Text] [Related]
15. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
[No Abstract] [Full Text] [Related]
16. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
[TBL] [Abstract][Full Text] [Related]
17. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
Kusano Y; Terui Y; Ueda K; Hatake K
Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
[No Abstract] [Full Text] [Related]
18. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Chen YH; Lee CH; Pei SN
Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
[No Abstract] [Full Text] [Related]
20. The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics.
Pieri L; Loiacono I; Vannucchi AM
Leuk Res; 2013 Aug; 37(8):855-6. PubMed ID: 23726413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
